EBC-46 in 2026: A Snapshot of the Global Regulatory Landscape
A neutral overview of where EBC-46 sits across veterinary approvals, human clinical development, and the US dietary supplement framework as of April 2026.
The regulatory status of EBC-46 — the small-molecule diterpene ester better known as tigilanol tiglate — continues to evolve along two parallel tracks in 2026. On the pharmaceutical side, QBiotics Group is advancing human clinical development while the veterinary product Stelfonta remains commercially available. On the consumer side, dietary supplement brands market whole-seed blushwood berry extracts under the US Dietary Supplement Health and Education Act (DSHEA), the established legal framework for botanical supplements.
Veterinary approvals remain the reference point
Stelfonta (tigilanol tiglate injection) was first approved by the US Food and Drug Administration in November 2020 for the treatment of non-metastatic mast cell tumours in dogs, following European approval earlier the same year. Those approvals have held steady through 2026, and Stelfonta is now distributed across several additional jurisdictions through Virbac. For a fuller technical history, see our complete guide to EBC-46 and tigilanol tiglate.
Human clinical development: Phase II into expanded indications
On the human side, QBiotics has publicly disclosed continued Phase II activity across squamous cell carcinoma of the head and neck, soft tissue sarcoma, and refractory solid tumours. The company’s pipeline disclosures describe an intratumoural route of administration — consistent with the mechanism of action reviewed in our article on PKC-delta activation and vascular disruption. Importantly, none of this clinical work involves oral dosing, and none of it is relevant to the supplement category directly.
The US dietary supplement framework
Consumer blushwood berry extract products fall under DSHEA, the 1994 statute that governs botanical supplements in the United States. Under DSHEA, products are regulated as food rather than drugs, which means they can be lawfully sold without the pre-market approval required for pharmaceuticals — but they must carry the standard FDA disclaimer and may not make disease claims. The FDA guidance on dietary supplements sets out the relevant labelling, manufacturing (cGMP), and adverse-event reporting expectations. This is a well-established framework; responsible brands like Blushwood Health explicitly position their tincture and capsule products within it and make no therapeutic claims.
What’s actually changing in 2026
The most visible shifts this year are incremental rather than structural. QBiotics’ ongoing trials generate periodic readouts; several EU member states have updated veterinary pharmacovigilance practice for Stelfonta; and on the supplement side, the conversation has shifted from "is this product real?" to "which suppliers meet the standards buyers should expect?" That last question is an industry-maturation question, not a regulatory one. The FDA’s cGMP guidance for dietary supplements remains the baseline, and brands that pair cGMP manufacturing with independent batch testing via accredited labs (Eurofins and similar) are the ones meeting the evidence bar buyers can reasonably ask for.
What this means for readers
For anyone tracking EBC-46: the veterinary pharmaceutical and the human supplement exist in different legal categories and should not be conflated. Stelfonta is a prescription veterinary drug. Blushwood berry extract supplements are DSHEA products intended as dietary supplements, not to diagnose, treat, cure or prevent any disease. The evidence bar for each is different by design, and both are operating within well-defined regulatory structures in 2026.
Related reading
• Fontainea picrosperma: seed chemistry and botanical origins
• Where to buy EBC-46: evaluating suppliers in 2026
